This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Delivered as Hybrid Event from 15-19 November 2021
Live In-Person Conference Delivered 15-17 NovemberSheraton Airport Brussels, Belgium

Shalini Andersson, PhD
Chief Scientist New Therapeutic Modalities at AstraZeneca

Profile

Shalini is currently the Chief Scientist and Head of Oligonucleotide Discovery at AstraZeneca. Shalini has broad experience in Pharmaceutical research as well as strategic and management roles. Shalini drives several collaborations with external partners and is also involved in several academic collaborations across the globe. Prior to this role, Shalini held several leadership roles in Drug Metabolism & Pharmacokinetics and Medicinal Chemistry. Shalini received her PhD in 1989 at the University of Linköping, Sweden and has held various research and teaching positions at the University of Linköping prior to moving to industry. She is the author or co-author of over 50 peer reviewed articles, 2 book chapters and 5 patents.

Agenda Sessions

  • Developing Oligonucleotides into Therapies: Opportunities and Challenges

    08:15